Regulation of reverse cholesterol transport - A comprehensive appraisal of available animal studies

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Annema, Wijtske ^a,b   Tietge, Uwe J F ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

Atherosclerosis; Bile; Cholesterol; Efflux; Feces; High density lipoproteins; Intestine; Liver; Macrophages; reverse cholesterol transport

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ANTIVIRUS AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CILOSTAZOL; FARNESOID X RECEPTOR; FERULIC ACID; FISH OIL; GLIBENCLAMIDE; GLIMEPIRIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NIEMANN PICK C1 LIKE 1 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PROTEASOME INHIBITOR; PROTEIN; SERUM AMYLOID A; SULFONYLUREA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; EXERCISE; FECES; FOAM CELL; HYDROLYSIS; INTESTINE ABSORPTION; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; REVERSE CHOLESTEROL TRANSPORT; REVIEW;

ANIMALIA;

EID: 84858982029     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-25     Document Type: Review

References (147)

1. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB, JAMA 1986 256 2835 2838 (Pubitemid 17178361)
2. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Assmann G, Schulte H, von Eckardstein A, Huang Y, Atherosclerosis 1996 124 11 S20
3. Major lipids, apolipoproteins, and risk of vascular disease. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, et al. JAMA 2009 302 1993 2000
4. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E, Lancet 2001 358 2026 2033 (Pubitemid 34084825)
5. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Lewis GF, Rader DJ, Circ Res 2005 96 1221 1232 (Pubitemid 40962099)
6. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Linsel-Nitschke P, Tall AR, Nat Rev Drug Discov 2005 4 193 205 (Pubitemid 40372554)
7. Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell? Rader DJ, Pure E, Cell Metab 2005 1 223 230 (Pubitemid 43960611)
8. The macrophage foam cell as a target for therapeutic intervention. Li AC, Glass CK, Nat Med 2002 8 1235 1242 (Pubitemid 35373554)
9. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Tabas I, Williams KJ, Boren J, Circulation 2007 116 1832 1844 (Pubitemid 350287108)
10. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Cuchel M, Rader DJ, Circulation 2006 113 2548 2555 (Pubitemid 43948034)
11. Molecular regulation of macrophage reverse cholesterol transport. Wang X, Rader DJ, Curr Opin Cardiol 2007 22 368 372 (Pubitemid 46897290)
12. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Calabresi L, Franceschini G, Trends Cardiovasc Med 2010 20 50 53
13. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR, Arterioscler Thromb Vasc Biol 2003 23 160 167 (Pubitemid 36231923)
14. Centripetal cholesterol flux to the liver is dictated by events in the peripheral organs and not by the plasma high density lipoprotein or apolipoprotein A-I concentration. Jolley CD, Woollett LA, Turley SD, Dietschy JM, J Lipid Res 1998 39 2143 2149 (Pubitemid 28523120)
15. Centripetal cholesterol flux from extrahepatic organs to the liver is independent of the concentration of high density lipoprotein-cholesterol in plasma. Osono Y, Woollett LA, Marotti KR, Melchior GW, Dietschy JM, Proc Natl Acad Sci USA 1996 93 4114 4119 (Pubitemid 26144251)
16. Centripetal cholesterol flow from the extrahepatic organs through the liver is normal in mice with mutated Niemann-Pick type C protein (NPC1). Xie C, Turley SD, Dietschy JM, J Lipid Res 2000 41 1278 1289 (Pubitemid 30666893)
17. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. Amar MJ, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, Remaley AT, J Pharmacol Exp Ther 2010 334 634 641
18. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ, Circulation 2003 108 661 663 (Pubitemid 36999247)
19. An alternative method to measure in vivo reverse cholesterol transport in hyperlipidemic hamsters. Briand F, Thieblemont Q, Muzotte E, Sulpice T, Circulation 2011 124 11835
20. Sterol efflux mediated by endogenous macrophage ApoE expression is independent of ABCA1. Huang ZH, Lin CY, Oram JF, Mazzone T, Arterioscler Thromb Vasc Biol 2001 21 2019 2025 (Pubitemid 34219756)
21. cAMP stimulates cholesteryl ester clearance to high density lipoproteins in J7774 macrophages. Bernard DW, Rodriguez A, Rothblat GH, Glick JM, J Biol Chem 1991 266 710 716 (Pubitemid 21907172)
22. Post-translational regulation of macrophage apoprotein E production. Mazzone T, Pustelnikas L, Reardon CA, J Biol Chem 1992 267 1081 1087
23. Distinct cellular loci for the ABCA1-dependent and ABCA1-independent lipid efflux mediated by endogenous apolipoprotein E expression. Huang ZH, Fitzgerald ML, Mazzone T, Arterioscler Thromb Vasc Biol 2006 26 157 162 (Pubitemid 43732243)
24. Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. Zanotti I, Pedrelli M, Poti F, Stomeo G, Gomaraschi M, Calabresi L, Bernini F, Arterioscler Thromb Vasc Biol 2011 31 74 80
25. The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. Marathe C, Bradley MN, Hong C, Lopez F, Ruiz de Galarreta CM, Tontonoz P, Castrillo A, J Biol Chem 2006 281 32197 32206 (Pubitemid 46036774)
26. LXRalpha regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Pourcet B, Feig JE, Vengrenyuk Y, Hobbs AJ, Kepka-Lenhart D, Garabedian MJ, Morris SM Jr, Fisher EA, Pineda-Torra I, Circ Res 2011 109 492 501
27. A novel in vivo assay for reverse cholesterol transport. Malik P, Smith JD, Arteriosclerosis Thrombosis and Vascular Biology 2009 29 46
28. Novel in vivo method for measuring cholesterol mass flux in peripheral macrophages. Weibel GL, Hayes S, Wilson A, Phillips MC, Billheimer J, Rader DJ, Rothblat GH, Arterioscler Thromb Vasc Biol 2011 31 2865 2871
29. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. Zhao B, Song J, Chow WN, St Clair RW, Rudel LL, Ghosh S, J Clin Invest 2007 117 2983 2992 (Pubitemid 47529628)
30. In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Wang MD, Franklin V, Marcel YL, Arterioscler Thromb Vasc Biol 2007 27 1837 1842 (Pubitemid 47208488)
31. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ, J Clin Invest 2007 117 2216 2224 (Pubitemid 47219566)
32. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Out R, Jessup W, Le Goff W, Hoekstra M, Gelissen IC, Zhao Y, Kritharides L, Chimini G, Kuiper J, Chapman MJ, et al. Circ Res 2008 102 113 120
33. Hypocholesterolemia, foam cell accumulation, but no atherosclerosis in mice lacking ABC-transporter A1 and scavenger receptor BI. Zhao Y, Pennings M, Vrins CL, Calpe-Berdiel L, Hoekstra M, Kruijt JK, Ottenhoff R, Hildebrand RB, van der Sluis R, Jessup W, et al. Atherosclerosis 2011 218 314 322
34. Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice. Samyn H, Moerland M, van Gent T, van Haperen R, Grosveld F, van Tol A, de Crom R, Atherosclerosis 2009 204 429 434
35. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Tchoua U, D'Souza W, Mukhamedova N, Blum D, Niesor E, Mizrahi J, Maugeais C, Sviridov D, Cardiovasc Res 2008 77 732 739 (Pubitemid 351301865)
36. CETP activity variation in mice does not affect two major HDL antiatherogenic properties: macrophage-specific reverse cholesterol transport and LDL antioxidant protection. Rotllan N, Calpe-Berdiel L, Guillaumet-Adkins A, Suren-Castillo S, Blanco-Vaca F, Escola-Gil JC, Atherosclerosis 2008 196 505 513
37. Overexpression of human 15(S)-lipoxygenase-1 in RAW macrophages leads to increased cholesterol mobilization and reverse cholesterol transport. Weibel GL, Joshi MR, Alexander ET, Zhu P, Blair IA, Rothblat GH, Arterioscler Thromb Vasc Biol 2009 29 837 842
38. Myeloid differentiation primary response protein 88 couples reverse cholesterol transport to inflammation. Smoak KA, Aloor JJ, Madenspacher J, Merrick BA, Collins JB, Zhu X, Cavigiolio G, Oda MN, Parks JS, Fessler MB, Cell Metab 2010 11 493 502
39. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, Rader DJ, Circ Res 2005 97 763 771 (Pubitemid 41447126)
40. Influence of apolipoprotein A-I domain structure on macrophage reverse cholesterol transport in mice. Alexander ET, Vedhachalam C, Sankaranarayanan S, de la Llera-Moya M, Rothblat GH, Rader DJ, Phillips MC, Arterioscler Thromb Vasc Biol 2011 31 320 327
41. Macrophage reverse cholesterol transport in mice expressing ApoA-I Milano. Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M, Rothblat GH, Phillips MC, Rader DJ, Arterioscler Thromb Vasc Biol 2009 29 1496 1501
42. The thienotriazolodiazepine Ro 11-1464 increases plasma apoA-I and promotes reverse cholesterol transport in human apoA-I transgenic mice. Zanotti I, Maugeais C, Pedrelli M, Gomaraschi M, Salgam P, Calabresi L, Bernini F, Kempen H, Br J Pharmacol 2011 164 1642 1651
43. Oral D-4 F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM, Circulation 2004 109 3215 3220
44. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S, J Lipid Res 2010 51 1496 1503
45. Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice. Calpe-Berdiel L, Rotllan N, Palomer X, Ribas V, Blanco-Vaca F, Escola-Gil JC, Biochim Biophys Acta 2005 1738 6 9 (Pubitemid 43122125)
46. Pharmacologic suppression of hepatic atp-binding cassette transporter 1 activity in mice reduces high-density lipoprotein cholesterol levels but promotes reverse cholesterol transport. Yamamoto S, Tanigawa H, Li X, Komaru Y, Billheimer JT, Rader DJ, Circulation 2011 124 1382 1390
47. Lecithin: Cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Tanigawa H, Billheimer JT, Tohyama J, Fuki IV, Ng DS, Rothblat GH, Rader DJ, Circulation 2009 120 160 169
48. Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins. Brown RJ, Lagor WR, Sankaranaravanan S, Yasuda T, Quertermous T, Rothblat GH, Rader DJ, Circ Res 2010 107 357 364
49. Hepatic proprotein convertases modulate HDL metabolism. Jin W, Wang X, Millar JS, Quertermous T, Rothblat GH, Glick JM, Rader DJ, Cell Metab 2007 6 129 136 (Pubitemid 47189092)
50. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, Rader DJ, Circulation 2007 116 1267 1273 (Pubitemid 47517538)
51. Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis. El Bouhassani M, Gilibert S, Moreau M, Saint-Charles F, Treguier M, Poti F, Chapman MJ, Le Goff W, Lesnik P, Huby T, J Biol Chem 2011 286 17227 17238
52. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, et al. J Lipid Res 2010 51 3443 3454
53. CETP inhibitor torcetrapib promotes reverse cholesterol transport in obese insulin-resistant cetp-apob100 transgenic mice. Briand F, Thieblemont Q, Andre A, Ouguerram K, Sulpice T, Clin Transl Sci 2011 4 414 420
54. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. Castro-Perez J, Briand F, Gagen K, Wang SP, Chen Y, McLaren DG, Shah V, Vreeken RJ, Hankemeier T, Sulpice T, et al. J Lipid Res 2011 52 1965 1973
55. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Rotllan N, Ribas V, Calpe-Berdiel L, Martin-Campos JM, Blanco-Vaca F, Escola-Gil JC, Arterioscler Thromb Vasc Biol 2005 25 128 132
56. Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo. Lagor WR, Brown RJ, Toh SA, Millar JS, Fuki IV, de la Llera-Moya M, Yuen T, Rothblat G, Billheimer JT, Rader DJ, Arterioscler Thromb Vasc Biol 2009 29 40 46
57. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ, J Clin Invest 2005 115 2870 2874 (Pubitemid 41434414)
58. P2Y13 receptor is critical for reverse cholesterol transport. Fabre AC, Malaval C, Ben Addi A, Verdier C, Pons V, Serhan N, Lichtenstein L, Combes G, Huby T, Briand F, et al. Hepatology 2010 52 1477 1483
59. Type I diabetes mellitus decreases in vivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice. de Boer JF, Annema W, Schreurs M, van der Veen JN, van der Giet M, Nijstad N, Kuipers F, Tietge UJ, J Lipid Res 2012 53 348 357
60. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, Levy AP, Circ Res 2006 99 1419 1425 (Pubitemid 44949678)
61. Hepatic overexpression of cholesteryl ester hydrolase enhances cholesterol elimination and in vivo reverse cholesterol transport. Zhao B, Song J, Ghosh S, J Lipid Res 2008 49 2212 2217
62. Reverse cholesterol transport is elevated in carboxyl ester lipase-knockout mice. Camarota LM, Woollett LA, Howles PN, FASEB J 2011 25 1370 1377
63. Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8. Calpe-Berdiel L, Rotllan N, Fievet C, Roig R, Blanco-Vaca F, Escola-Gil JC, J Lipid Res 2008 49 1904 1911
64. Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ, Gastroenterology 2011 140 1043 1051
65. Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Temel RE, Sawyer JK, Yu L, Lord C, Degirolamo C, McDaniel A, Marshall S, Wang N, Shah R, Rudel LL, Brown JM, Cell Metab 2010 12 96 102
66. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Briand F, Naik SU, Fuki I, Millar JS, Macphee C, Walker M, Billheimer J, Rothblat G, Rader DJ, Clin Transl Sci 2009 2 127 133
67. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Sehayek E, Hazen SL, Arterioscler Thromb Vasc Biol 2008 28 1296 1297
68. Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect. Greenberg ME, Smith JD, Sehayek E, Arterioscler Thromb Vasc Biol 2009 29 1745 1750
69. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). Annema W, Nijstad N, Tolle M, de Boer JF, Buijs RV, Heeringa P, van der Giet M, Tietge UJ, J Lipid Res 2010 51 743 754
70. Inflammation impairs reverse cholesterol transport in vivo. McGillicuddy FC, de la Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP, Circulation 2009 119 1135 1145
71. Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport. Malik P, Berisha SZ, Santore J, Agatisa-Boyle C, Brubaker G, Smith JD, J Lipid Res 2011 52 951 957
72. Mast cell activation in vivo impairs the macrophage reverse cholesterol transport pathway in the mouse. Lee-Rueckert M, Silvennoinen R, Rotllan N, Judstrom I, Blanco-Vaca F, Metso J, Jauhiainen M, Kovanen PT, Escola-Gil JC, Arterioscler Thromb Vasc Biol 2011 31 520 527
73. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ, Circulation 2006 113 90 97 (Pubitemid 43958493)
74. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Yasuda T, Grillot D, Billheimer JT, Briand F, Delerive P, Huet S, Rader DJ, Arterioscler Thromb Vasc Biol 2010 30 781 786
75. The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. Zanotti I, Poti F, Pedrelli M, Favari E, Moleri E, Franceschini G, Calabresi L, Bernini F, J Lipid Res 2008 49 954 960
76. Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model. Briand F, Treguier M, Andre A, Grillot D, Issandou M, Ouguerram K, Sulpice T, J Lipid Res 2010 51 763 770
77. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Lo Sasso G, Murzilli S, Salvatore L, D'Errico I, Petruzzelli M, Conca P, Jiang ZY, Calabresi L, Parini P, Moschetta A, Cell Metab 2010 12 187 193
78. Peroxisome proliferator-activated receptor-alpha activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway. Nakaya K, Tohyama J, Naik SU, Tanigawa H, MacPhee C, Billheimer JT, Rader DJ, Arterioscler Thromb Vasc Biol 2011 31 1276 1282
79. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Rotllan N, Llaverias G, Julve J, Jauhiainen M, Calpe-Berdiel L, Hernandez C, Simo R, Blanco-Vaca F, Escola-Gil JC, Biochim Biophys Acta 2011 1811 104 110
80. PPARgamma activation redirects macrophage cholesterol from fecal excretion to adipose tissue uptake in mice via SR-BI. Toh SA, Millar JS, Billheimer J, Fuki I, Naik SU, Macphee C, Walker M, Rader DJ, Biochem Pharmacol 2011 81 934 941
81. Identification of novel pathways that control farnesoid X receptor-mediated hypocholesterolemia. Zhang Y, Yin L, Anderson J, Ma H, Gonzalez FJ, Willson TM, Edwards PA, J Biol Chem 2010 285 3035 3043
82. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, et al. J Clin Invest 2011 121 2921 2931
83. The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice. Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, et al. PLoS One 2010 5 8722
84. Effect of sulfonylurea agents on reverse cholesterol transport in vitro and vivo. Terao Y, Ayaori M, Ogura M, Yakushiji E, Uto-Kondo H, Hisada T, Ozasa H, Takiguchi S, Nakaya K, Sasaki M, et al. J Atheroscler Thromb 2011 18 513 530
85. Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. Tohyama J, Billheimer JT, Fuki IV, Rothblat GH, Rader DJ, Millar JS, Atherosclerosis 2009 204 418 423
86. Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo. Nakaya K, Ayaori M, Uto-Kondo H, Hisada T, Ogura M, Yakushiji E, Takiguchi S, Terao Y, Ozasa H, Sasaki M, et al. Atherosclerosis 2010 213 135 141
87. Proteasomal Inhibition Promotes ATP-Binding Cassette Transporter A1 (ABCA1) and ABCG1 expression and cholesterol efflux from macrophages in vitro and in vivo. Ogura M, Ayaori M, Terao Y, Hisada T, Iizuka M, Takiguchi S, Uto-Kondo H, Yakushiji E, Nakaya K, Sasaki M, et al. Arterioscler Thromb Vasc Biol 2011 31 1980 1987
88. Ethanolic extract of propolis promotes reverse cholesterol transport and the expression of ATP-binding cassette transporter A1 and G1 in mice. Yu Y, Si Y, Song G, Luo T, Wang J, Qin S, Lipids 2011 46 805 811
89. Diet-induced dyslipidemia impairs reverse cholesterol transport in hamsters. Treguier M, Briand F, Boubacar A, Andre A, Magot T, Nguyen P, Krempf M, Sulpice T, Ouguerram K, Eur J Clin Invest 2011 41 921 928
90. The Cholesterol Content of Western Diets Plays a Major Role in the Paradoxical Increase in High-Density Lipoprotein Cholesterol and Upregulates the Macrophage Reverse Cholesterol Transport Pathway. Escola-Gil JC, Llaverias G, Julve J, Jauhiainen M, Mendez-Gonzalez J, Blanco Vaca F, Arterioscler Thromb Vasc Biol 2011 31 2493 2499
91. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages. Uto-Kondo H, Ayaori M, Ogura M, Nakaya K, Ito M, Suzuki A, Takiguchi S, Yakushiji E, Terao Y, Ozasa H, et al. Circ Res 2010 106 779 787
92. Fish oil promotes macrophage reverse cholesterol transport in mice. Nishimoto T, Pellizzon MA, Aihara M, Stylianou IM, Billheimer JT, Rothblat G, Rader DJ, Arterioscler Thromb Vasc Biol 2009 29 1502 1508
93. Voluntary exercise increases cholesterol efflux but not macrophage reverse cholesterol transport in vivo in mice. Meissner M, Nijstad N, Kuipers F, Tietge UJ, Nutr Metab (Lond) 2010 7 54
94. Aerobic exercise improves reverse cholesterol transport in cholesteryl ester transfer protein transgenic mice. Rocco DD, Okuda LS, Pinto RS, Ferreira FD, Kubo SK, Nakandakare ER, Quintao EC, Catanozi S, Passarelli M, Lipids 2011 46 617 625
95. Mobilization of cytoplasmic CE droplets by overexpression of human macrophage cholesteryl ester hydrolase. Ghosh S, St Clair RW, Rudel LL, J Lipid Res 2003 44 1833 1840 (Pubitemid 37356655)
96. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB, Tall AR, J Biol Chem 1997 272 20982 20985 (Pubitemid 27373951)
97. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Covey SD, Krieger M, Wang W, Penman M, Trigatti BL, Arterioscler Thromb Vasc Biol 2003 23 1589 1594 (Pubitemid 37108202)
98. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein E-deficient mice. Zhang W, Yancey PG, Su YR, Babaev VR, Zhang Y, Fazio S, Linton MF, Circulation 2003 108 2258 2263 (Pubitemid 37363044)
99. Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT, Van Berkel TJ, Am J Pathol 2004 165 785 794 (Pubitemid 39129286)
100. Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3. Mazzone T, Reardon C, J Lipid Res 1994 35 1345 1353 (Pubitemid 24251029)
101. Apolipoprotein E-dependent cholesterol efflux from macrophages: kinetic study and divergent mechanisms for endogenous versus exogenous apolipoprotein E. Lin CY, Duan H, Mazzone T, J Lipid Res 1999 40 1618 1627
102. Endogenous apolipoprotein E modulates cholesterol efflux and cholesteryl ester hydrolysis mediated by high-density lipoprotein-3 and lipid-free apolipoproteins in mouse peritoneal macrophages. Langer C, Huang Y, Cullen P, Wiesenhutter B, Mahley RW, Assmann G, von Eckardstein A, J Mol Med (Berl) 2000 78 217 227 (Pubitemid 30432012)
103. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, et al. JAMA 2003 290 2292 2300 (Pubitemid 37430562)
104. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, et al. JAMA 2007 297 1675 1682 (Pubitemid 46631626)
105. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith TL, et al. J Clin Invest 2005 115 1333 1342 (Pubitemid 40629053)
106. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, et al. J Clin Invest 2006 116 1052 1062
107. ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism. Drobnik W, Lindenthal B, Lieser B, Ritter M, Christiansen Weber T, Liebisch G, Giesa U, Igel M, Borsukova H, Buchler C, et al. Gastroenterology 2001 120 1203 1211 (Pubitemid 32246674)
108. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Annema W, Tietge UJ, Curr Atheroscler Rep 2011 13 257 265
109. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C, Atherosclerosis 2001 155 269 281 (Pubitemid 32209296)
110. Apolipoprotein A-II, HDL metabolism and atherosclerosis. Tailleux A, Duriez P, Fruchart JC, Clavey V, Atherosclerosis 2002 164 1 13 (Pubitemid 34765632)
111. Cell surface adenylate kinase activity regulates the F(1)-ATPase/P2Y (13)-mediated HDL endocytosis pathway on human hepatocytes. Fabre AC, Vantourout P, Champagne E, Terce F, Rolland C, Perret B, Collet X, Barbaras R, Martinez LO, Cell Mol Life Sci 2006 63 2829 2837 (Pubitemid 44913322)
112. Hepatic SR-BI, not endothelial lipase, expression determines biliary cholesterol secretion in mice. Wiersma H, Gatti A, Nijstad N, Kuipers F, Tietge UJ, J Lipid Res 2009 50 1571 1580
113. Scavenger receptor class B type I mediates biliary cholesterol secretion independent of ATP-binding cassette transporter g5/g8 in mice. Wiersma H, Gatti A, Nijstad N, Oude Elferink RP, Kuipers F, Tietge UJ, Hepatology 2009 50 1263 1272
114. Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion. Tietge UJ, Nijstad N, Havinga R, Baller JF, van der Sluijs FH, Bloks VW, Gautier T, Kuipers F, J Lipid Res 2008 49 563 571
115. Biliary cholesterol secretion: more than a simple ABC. Dikkers A, Tietge UJ, World J Gastroenterol 2010 16 5936 5945
116. NPC2 regulates biliary cholesterol secretion via stimulation of ABCG5/G8-mediated cholesterol transport. Yamanashi Y, Takada T, Yoshikado T, Shoda J, Suzuki H, Gastroenterology 2011 140 1664 1674
117. Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH, Proc Natl Acad Sci USA 2002 99 16237 16242 (Pubitemid 35462779)
118. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Kruit JK, Plosch T, Havinga R, Boverhof R, Groot PH, Groen AK, Kuipers F, Gastroenterology 2005 128 147 156 (Pubitemid 40039966)
119. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. van der Velde AE, Vrins CL, van den Oever K, Kunne C, Oude Elferink RP, Kuipers F, Groen AK, Gastroenterology 2007 133 967 975 (Pubitemid 47374133)
120. Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. Brown JM, Bell TA, Sawyer JK, Smith TL, Kelley K, Shah R, Wilson MD, Davis MA, Lee RG, et al. J Biol Chem 2008 283 10522 10534
121. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. van der Veen JN, van Dijk TH, Vrins CL, van Meer H, Havinga R, Bijsterveld K, Tietge UJ, Groen AK, Kuipers F, J Biol Chem 2009 284 19211 19219
122. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, et al. Science 2004 303 1201 1204 (Pubitemid 38233587)
123. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, et al. Proc Natl Acad Sci USA 2005 102 8132 8137 (Pubitemid 40800055)
124. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, Hobbs HH, J Clin Invest 2002 110 671 680 (Pubitemid 34988791)
125. Endotoxin, TNF, and IL-1 decrease cholesterol 7 alpha-hydroxylase mRNA levels and activity. Feingold KR, Spady DK, Pollock AS, Moser AH, Grunfeld C, J Lipid Res 1996 37 223 228 (Pubitemid 26078941)
126. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. potential role of hepatocyte nuclear factor-1. Memon RA, Moser AH, Grunfeld C, Feingold KR, J Biol Chem 2001 276 30118 30126
127. Mast cells in vulnerable coronary plaques: potential mechanisms linking mast cell activation to plaque erosion and rupture. Lindstedt KA, Kovanen PT, Curr Opin Lipidol 2004 15 567 573 (Pubitemid 39336585)
128. The liver X receptor gene team: potential new players in atherosclerosis. Repa JJ, Mangelsdorf DJ, Nat Med 2002 8 1243 1248 (Pubitemid 35373555)
129. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P, Proc Natl Acad Sci USA 2000 97 12097 12102
130. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Wang N, Ranalletta M, Matsuura F, Peng F, Tall AR, Arterioscler Thromb Vasc Biol 2006 26 1310 1316 (Pubitemid 44305375)
131. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Gross B, Staels B, Best Pract Res Clin Endocrinol Metab 2007 21 687 710 (Pubitemid 350177568)
132. Roles of PPARs in health and disease. Kersten S, Desvergne B, Wahli W, Nature 2000 405 421 424 (Pubitemid 30367411)
133. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Chinetti G, Fruchart JC, Staels B, Inflamm Res 2000 49 497 505
134. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. Li AC, Glass CK, J Lipid Res 2004 45 2161 2173 (Pubitemid 39602963)
135. Peroxisome proliferator-activated receptors-from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. Bouhlel MA, Staels B, Chinetti-Gbaguidi G, J Intern Med 2008 263 28 42 (Pubitemid 350243555)
136. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Barter PJ, Rye KA, Arterioscler Thromb Vasc Biol 2008 28 39 46
137. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, Diabetes Care 2005 28 1547 1554 (Pubitemid 40923063)
138. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. Polonsky T, Mazzone T, Davidson M, Trends Cardiovasc Med 2009 19 94 99
139. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Duez H, Lefebvre B, Poulain P, Torra IP, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, et al. Arterioscler Thromb Vasc Biol 2005 25 585 591 (Pubitemid 40315682)
140. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, et al. Proc Natl Acad Sci USA 2001 98 5306 5311 (Pubitemid 32397124)
141. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1. van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F, J Lipid Res 2005 46 526 534 (Pubitemid 43109789)
142. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, et al. Arterioscler Thromb Vasc Biol 2001 21 372 377 (Pubitemid 32199118)
143. FXR, a multipurpose nuclear receptor. Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y, Trends Biochem Sci 2006 31 572 580 (Pubitemid 44436939)
144. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM, Science 2010 328 1566 1569
145. miR-33 links SREBP-2 induction to repression of sterol transporters. Marquart TJ, Allen RM, Ory DS, Baldan A, Proc Natl Acad Sci USA 2010 107 12228 12232
146. Dietary saturated and trans fatty acids and cholesterol and 25-year mortality from coronary heart disease: the seven countries study. Kromhout D, Menotti A, Bloemberg B, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, Giampaoli S, Jansen A, et al. Prev Med 1995 24 308 315
147. Voluntary wheel running increases bile acid as well as cholesterol excretion and decreases atherosclerosis in hypercholesterolemic mice. Meissner M, Lombardo E, Havinga R, Tietge UJ, Kuipers F, Groen AK, Atherosclerosis 2011 218 323 329